"Cardiac glycosides"-quo vaditis?-past, present, and future?
Julia FenderJohanna KlöckerValérie Boivin-JahnsUrsula RavensRoland JahnsKristina LorenzPublished in: Naunyn-Schmiedeberg's archives of pharmacology (2024)
Up to date, digitalis glycosides, also known as "cardiac glycosides", are inhibitors of the Na + /K + -ATPase. They have a long-standing history as drugs used in patients suffering from heart failure and atrial fibrillation despite their well-known narrow therapeutic range and the intensive discussions on their raison d'être for these indications. This article will review the history and key findings in basic and clinical research as well as potentially overseen pros and cons of these drugs.
Keyphrases
- heart failure
- atrial fibrillation
- left ventricular
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- coronary artery disease
- patient reported outcomes
- oral anticoagulants
- direct oral anticoagulants
- venous thromboembolism
- mitral valve
- left atrial appendage
- patient reported
- cardiac resynchronization therapy
- advance care planning